Ayala Pharmaceuticals, Inc.
Ayala Pharmaceuticals, Inc. (ADXS) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
adxs · pe ratio · data through Dec 31, 2023
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Ayala Pharmaceuticals, Inc. (ADXS) measures how much investors pay for each dollar of the company's trailing earnings. ADXS's current PE ratio of N/A is calculated by dividing its stock price of $0.60 by its TTM earnings per share of -$7.99.
Source: FMP · /ratios-ttm · /analyst-estimates · 2023-12-31
PE Ratio History
2005 – 2023 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Ayala Pharmaceuticals, Inc.You ADXS | $26M | N/A | — | -$7.99 |
 America Great Health AAGH | $4M | N/A | — | -$0.00 |
 Algernon Pharmaceuticals Inc. AGNPF | $2M | N/A | — | -$0.58 |
 Agentix Corp. AGTX | $1M | N/A | — | -$0.01 |
 Appili Therapeutics Inc. APLIF | $2M | N/A | — | -$0.02 |
 Health Sciences Group, Inc. HESG | $2M | N/A | — | -$0.03 |
 Universal Ibogaine Inc. IBOGF | $9M | N/A | — | -$0.06 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2023-12-31Latest FY2023 | — | $-7.99 | — | |
2022-12-31 FY2022 | — | $-7.90 | — | |
2022-01-31 FY2022 | — | $-11.07 | — | |
2021-01-31 FY2021 | — | $-34.71 | — | |
2020-01-31 FY2020 | — | $-93.60 | — | |
2019-01-31 FY2019 | — | $-19.37 | — | |
2018-01-31 FY2018 | — | $-34.58 | — | |
2017-01-31 FY2017 | — | $-31.17 | — | |
2016-01-31 FY2016 | — | $-25.17 | — | |
2015-01-31 FY2015 | — | $-14.49 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Ayala Pharmaceuticals, Inc. (ADXS) measures how much investors pay for each dollar of the company's trailing earnings. ADXS's current PE ratio of N/A is calculated by dividing its stock price of $0.60 by its TTM earnings per share of -$7.99.
Frequently asked questions
ADXS pe ratio · 6 questionsADXS's current PE ratio is N/A as of 2026-06-15, based on a stock price of $0.60 and TTM EPS of -$7.99. Data sourced from Financial Modeling Prep via ADXS's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Ayala Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-15